IMNM · Immunome Inc. Common Stock
View on chartInsiders & Stakes
| RAPP MICHAEL Director | ▲ Buy | Grant | 1,071,172 Shares held | 10/2/2023 | View profile |
| Clay B. Siegall President and CEO | ▲ Buy | Grant | 870,704 Shares held | 7/23/2026 | View profile |
| Philip Wagenheim Director | ▼ Sell | Open Market | 341,147 Shares held | 3/23/2026 | View profile |
| Max Rosett Chief Financial Officer | ▲ Buy | Grant | 101,287 Shares held | 7/23/2026 | View profile |
| Isaac Barchas | ▼ Sell | Open Market | 92,211 Shares held | 8/12/2026 | View profile |
| Philip Tsai Chief Technology Officer | ▲ Buy | Grant | 81,550 Shares held | 7/23/2026 | View profile |
| Robert Lechleider Chief Medical Officer | ▲ Buy | Grant | 69,805 Shares held | 7/23/2026 | View profile |
| LAMATTINA JOHN L Director | ▲ Buy | Grant | 66,953 Shares held | 1/15/2023 | View profile |
| PRENDERGAST FRANKLYN G Director | ▲ Buy | Grant | 60,840 Shares held | 10/2/2023 | View profile |
| Jack Higgins Chief Scientific Officer | ▼ Sell | Gift | 56,250 Shares held | 9/11/2026 | View profile |
| Sandra G. Stoneman CHIEF LEGAL OFFICER & GC | ▲ Buy | Grant | 43,805 Shares held | 7/23/2026 | View profile |
| Jean Jacques Bienaime Chief Executive Officer | ▲ Buy | Open Market | 43,415 Shares held | 6/5/2026 | View profile |
| Turner Bruce Chief Strategy Officer | ▲ Buy | Open Market | 42,300 Shares held | 10/2/2023 | View profile |
| Lefenfeld Michael Director | ▲ Buy | Grant | 40,747 Shares held | 1/15/2023 | View profile |
| Kinney Horn CHIEF BUSINESS OFFICER | ▼ Sell | Open Market | 0 Shares held | 8/4/2026 | View profile |
Transaction History
| Jack Higgins | ▲ Buy | Option Exercise | 18,000 | $24K | 9/11/2026 |
| Jack Higgins | ▼ Sell | Open Market | 13,200 | $334K | 9/11/2026 |
| Jack Higgins | ▼ Sell | Gift | 8,800 | $0 | 9/11/2026 |
| Isaac Barchas | ▼ Sell | Open Market | 11,048 | $301K | 8/12/2026 |
| Isaac Barchas | ▼ Sell | Open Market | 62,291 | $1.6M | 8/11/2026 |
| Isaac Barchas | ▼ Sell | Open Market | 10,125 | $264K | 8/10/2026 |
| Isaac Barchas | ▼ Sell | Open Market | 15,248 | $397K | 8/7/2026 |
| Isaac Barchas | ▼ Sell | Open Market | 20,840 | $543K | 8/6/2026 |
| Kinney Horn | ▲ Buy | Option Exercise | 50,366 | $651K | 8/4/2026 |
| Kinney Horn | ▲ Buy | Option Exercise | 40,250 | $427K | 8/4/2026 |
| Kinney Horn | ▼ Sell | Open Market | 90,616 | $2.3M | 8/4/2026 |
| Kinney Horn | ▲ Buy | Grant | 31,250 | $0 | 7/23/2026 |
| Philip Tsai | ▲ Buy | Grant | 38,250 | $0 | 7/23/2026 |
| Sandra G. Stoneman | ▲ Buy | Grant | 38,250 | $0 | 7/23/2026 |
| Jack Higgins | ▲ Buy | Grant | 38,250 | $0 | 7/23/2026 |
| Max Rosett | ▲ Buy | Grant | 47,250 | $0 | 7/23/2026 |
| Robert Lechleider | ▲ Buy | Grant | 54,000 | $0 | 7/23/2026 |
| Clay B. Siegall | ▲ Buy | Grant | 180,000 | $0 | 7/23/2026 |
| Kinney Horn | ▲ Buy | Option Exercise | 1,092 | $14K | 7/7/2026 |
| Kinney Horn | ▼ Sell | Open Market | 1,092 | $27K | 7/7/2026 |
| Isaac Barchas | ▼ Sell | Open Market | 16,906 | $409K | 7/7/2026 |
| Isaac Barchas | ▼ Sell | Open Market | 83,094 | $2.0M | 7/6/2026 |
| Robert Lechleider | ▲ Buy | Option Exercise | 55,000 | $480K | 7/2/2026 |
| Robert Lechleider | ▼ Sell | Open Market | 22,714 | $499K | 7/2/2026 |
| Robert Lechleider | ▼ Sell | Open Market | 16,214 | $369K | 7/2/2026 |
| Robert Lechleider | ▼ Sell | Open Market | 16,072 | $377K | 7/2/2026 |
| Isaac Barchas | ▼ Sell | Open Market | 75,665 | $1.7M | 7/2/2026 |
| Isaac Barchas | ▼ Sell | Open Market | 24,335 | $568K | 7/2/2026 |
| Isaac Barchas | ▼ Sell | Open Market | 101,050 | $2.1M | 6/30/2026 |
| Robert Lechleider | ▼ Sell | Open Market | 40,580 | $794K | 6/25/2026 |
| Robert Lechleider | ▼ Sell | Open Market | 14,420 | $298K | 6/25/2026 |
| Robert Lechleider | ▲ Buy | Option Exercise | 55,000 | $480K | 6/25/2026 |
| Max Rosett | ▲ Buy | Option Exercise | 60,000 | $63K | 6/15/2026 |
| Max Rosett | ▼ Sell | Open Market | 60,000 | $1.1M | 6/15/2026 |
| Jean Jacques Bienaime | ▼ Sell | Open Market | 500 | $10K | 6/5/2026 |
| Jean Jacques Bienaime | ▼ Sell | Open Market | 10,000 | $194K | 6/5/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 6,000 | $117K | 6/5/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 3,500 | $68K | 6/5/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 1,000 | $19K | 6/5/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 5,000 | $104K | 5/15/2026 |
| Jack Higgins | ▼ Sell | Open Market | 9,438 | $204K | 4/2/2026 |
| Max Rosett | ▲ Buy | Option Exercise | 31,848 | $33K | 4/2/2026 |
| Max Rosett | ▲ Buy | Option Exercise | 39,713 | $54K | 4/2/2026 |
| Max Rosett | ▼ Sell | Open Market | 63,656 | $1.4M | 4/2/2026 |
| Max Rosett | ▼ Sell | Open Market | 1,344 | $30K | 4/2/2026 |
| Jack Higgins | ▼ Sell | Gift | 6,291 | $0 | 3/30/2026 |
| Clay B. Siegall | ▲ Buy | Open Market | 25,450 | $501K | 3/27/2026 |
| Philip Wagenheim | ▼ Sell | Open Market | 28,200 | $582K | 3/23/2026 |
| Philip Wagenheim | ▼ Sell | Open Market | 36,800 | $753K | 3/20/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 1,000 | $22K | 3/11/2026 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 1,000 | $22K | 3/10/2026 |
| Clay B. Siegall | ▲ Buy | Open Market | 4,729 | $100K | 12/30/2025 |
| Isaac Barchas | ▼ Sell | Open Market | 371,949 | $8.1M | 12/22/2025 |
| Isaac Barchas | ▼ Sell | Open Market | 11,251 | $251K | 12/22/2025 |
| Jack Higgins | ▼ Sell | Gift | 1,000 | $0 | 12/19/2025 |
| Jack Higgins | ▼ Sell | Gift | 1,000 | $0 | 12/19/2025 |
| Jack Higgins | ▼ Sell | Gift | 1,000 | $0 | 12/19/2025 |
| Jack Higgins | ▼ Sell | Gift | 1,000 | $0 | 12/19/2025 |
| Jack Higgins | ▼ Sell | Gift | 1,000 | $0 | 12/19/2025 |
| Jack Higgins | ▼ Sell | Gift | 1,000 | $0 | 12/19/2025 |
| Clay B. Siegall | ▲ Buy | Open Market | 7,278 | $149K | 12/19/2025 |
| Clay B. Siegall | ▼ Sell | Gift | 200,000 | $0 | 12/19/2025 |
| Philip Tsai | ▲ Buy | Open Market | 10,000 | $205K | 12/19/2025 |
| Clay B. Siegall | ▲ Buy | Open Market | 46,511 | $1000K | 12/18/2025 |
| Jack Higgins | ▲ Buy | Option Exercise | 22,000 | $30K | 9/10/2025 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 5,000 | $47K | 6/3/2025 |
| Jack Higgins | ▲ Buy | Option Exercise | 5,200 | $7K | 3/27/2025 |
| Clay B. Siegall | ▲ Buy | Open Market | 137,100 | $999K | 3/26/2025 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 7,800 | $61K | 3/25/2025 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 7,000 | $57K | 3/24/2025 |
| Philip Tsai | ▲ Buy | Open Market | 12,300 | $104K | 3/24/2025 |
| Clay B. Siegall | ▲ Buy | Open Market | 150,000 | $1.2M | 1/31/2025 |
| Clay B. Siegall | ▲ Buy | Open Market | 33,943 | $332K | 11/22/2024 |
| Clay B. Siegall | ▲ Buy | Open Market | 66,057 | $630K | 11/21/2024 |
| Philip Tsai | ▲ Buy | Open Market | 21,000 | $198K | 11/21/2024 |
| Robert Lechleider | ▲ Buy | Open Market | 15,805 | $150K | 11/21/2024 |
| Max Rosett | ▲ Buy | Option Exercise | 42,000 | $44K | 9/19/2024 |
| Max Rosett | ▼ Sell | Open Market | 14,380 | $230K | 9/19/2024 |
| Jack Higgins | ▼ Sell | Gift | 2,471 | $0 | 8/19/2024 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 7,000 | $98K | 8/16/2024 |
| Jack Higgins | ▲ Buy | Option Exercise | 19,524 | $26K | 8/15/2024 |
| Jack Higgins | ▼ Sell | Open Market | 3,524 | $49K | 8/15/2024 |
| Jean Jacques Bienaime | ▲ Buy | Open Market | 2,000 | $27K | 5/21/2024 |
| Clay B. Siegall | ▲ Buy | Open Market | 20,434 | $282K | 5/21/2024 |
| Clay B. Siegall | ▲ Buy | Open Market | 79,566 | $1.1M | 5/20/2024 |
| Clay B. Siegall | ▲ Buy | Open Market | 169,204 | $1000K | 10/2/2023 |
| Turner Bruce | ▲ Buy | Open Market | 42,300 | $250K | 10/2/2023 |
| PRENDERGAST FRANKLYN G | ▲ Buy | Grant | 60,840 | $0 | 10/2/2023 |
| RAPP MICHAEL | ▲ Buy | Grant | 253,806 | $1.5M | 10/2/2023 |
| RAPP MICHAEL | ▲ Buy | Grant | 17,500 | $70K | 1/15/2023 |
| Philip Wagenheim | ▲ Buy | Grant | 8,750 | $35K | 1/15/2023 |
| LAMATTINA JOHN L | ▲ Buy | Grant | 15,125 | $61K | 1/15/2023 |
| Lefenfeld Michael | ▲ Buy | Grant | 13,875 | $56K | 1/15/2023 |
| RAPP MICHAEL | ▲ Buy | Open Market | 25,962 | $518K | 9/13/2021 |
| RAPP MICHAEL | ▲ Buy | Open Market | 15,500 | $277K | 9/10/2021 |
| RAPP MICHAEL | ▲ Buy | Open Market | 8,170 | $142K | 9/9/2021 |
| RAPP MICHAEL | ▲ Buy | Open Market | 22,280 | $411K | 9/9/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Immunome files Nasdaq inducement grant report, sees higher volume
Immunome disclosed inducement grants in a filing required by Nasdaq Listing Rule 5635(c)(4). The disclosure shows the company is meeting reporting obligations for equity compensation. At the same time, the stock appeared among Benzinga’s recent volume movers, indicating a noticeable increase in trading activity. These items together suggest regulatory compliance and heightened market attention.
Immunome files Nasdaq inducement grant report, sees higher volume. Immunome disclosed inducement grants in a filing required by Nasdaq Listing Rule 5635(c)(4). The disclosure shows the company is meeting reporting obligations for equity compensation. At the same time, the stock appeared among Benzinga’s recent volume movers, indicating a noticeable increase in trading activity. These items together suggest regulatory compliance and heightened market attention.